GlassScriptPhysician profile
Chuan L Miao
NPI 1962660696
$5,472.47
in general payments reported to CMS, 2019-2025
31 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $439 · 2021: $751 · 2022: $774 · 2023: $1,016 · 2024: $789 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.46 | 2019-2025 | |
| Janssen Biotech, INC. | $881.01 | 2019-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $796.35 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $667.64 | 2019-2023 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $416.41 | 2019-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $237.16 | 2024-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $184.89 | 2020-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $162.76 | 2024-2025 | Iqirvo |
| Pfizer INC. | $148.04 | 2022-2025 | |
| Novo Nordisk INC | $144.76 | 2025 | Wegovy |
| Intera Oncology, INC | $128.75 | 2024 | Intera |
| Ucb, INC. | $87.03 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $73.35 | 2023-2024 | Terlivaz |
| Dova Pharmaceuticals | $68.40 | 2019 | |
| Merck Sharp & Dohme LLC | $62.56 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $56.17 | 2022 | |
| Genentech USA, INC. | $55.89 | 2023 | Avastin, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $51.96 | 2024-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $40.97 | 2021-2022 | |
| Ardelyx, INC. | $37.25 | 2023 | Ibsrela |
| Celgene Corporation | $35.53 | 2023 | Zeposia |
| Amgen INC. | $32.50 | 2023 | Amjevita |
| Axonics, INC. | $27.43 | 2022-2023 | Axonics |
| Genzyme Corporation | $24.46 | 2023 | |
| Ironwood Pharmaceuticals, INC | $21.80 | 2022 | |
| Shionogi INC | $21.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.29 | 2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $15.81 | 2024 | |
| W. L. Gore & Associates, INC. | $14.85 | 2020 | |
| Braintree Laboratories, INC. | $12.34 | 2019 | |
| Shire North American Group INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chuan Miao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.